Psoriasis - Anti-TNF's lead another indication

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2006-12-21

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

There is no cure for psoriasis, which profoundly affects sufferers quality of life, physical and social functioning. There is a particular unmet need for effective long-term therapies for psoriasis. Prevalence is the highest of the autoimmune diseases at 16 million in 2006, but this is deceptive in terms of market size, as the treated and severe patient populations are comparatively small.


Scope

  • Psoriasis specific ten year forecasts, contrasted against estimated total brand sales for key products
  • Sales and volume estimates, by indication from 2005-2015, for the US, combined five major EU markets and Japan
  • Analysis of late-stage pipeline products for psoriasis
  • Discussion of key events that affect the sales and volume of key brands


    • Report Highlights
    The disappointment of initial biologics in psoriasis and the fact that a higher dose tends to be required from biologics to achieve efficacy can be off-putting to companies. However, Enbrel's success, with an estimated $933 m in sales in the seven major markets for psoriatic conditions in 2005, shows that this market is not to be neglected.

    In a market driven by product switching, long term safety and efficacy is elusive. Year long trial data as exemplified by market leading biologics, is key and should be applied to all psoriasis products, be they biologic, traditional systemic or topical therapies.

    Approval in psoriatic arthritis appears to add force to uptake in psoriasis but is not a key indication in itself. Novel therapeutics expanding from rheumatology indications should consider this strategy, but Enbrel has paved the way for anti-TNF therapies to launch directly in psoriasis.


    Reasons to Purchase

  • Compare psoriasis forecasts with total brand sales for key existing products
  • Estimate the size of the psoriasis market to 2015
  • Benchmark late-stage pipeline products against the market leader

    • Table of Contents

    Other users found this report page using the following search terms: psoriasis autoimmune humira moredrug_warnings_recalls pen use humira patent expiry usa amevive antitnf sales

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.